← Return to all swing-trade opportunities
VRTX — Oversold Bullish Reversal
Status: Invalidated
Scanner score: 20.0/100
Why this was flagged
VRTX was identified as a bullish technical setup based on the Oversold Bullish Reversal pattern. The scanner found a score of 20.0/100 using trend alignment, momentum, price action, volume, and risk-management rules. Monitor update: Latest daily-chart analysis no longer reports a bullish long setup.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
The scanner found Vertex Pharmaceuticals Inc (VRTX) using a pattern called an Oversold Bullish Reversal. This means the stock price dropped quite a bit, and the Relative Strength Index (RSI) is at 19. RSI is a tool used to see if a stock has been sold too much. When the RSI is very low, it can sometimes mean the selling might stop soon. The scanner gave this setup a score of 20 out of 100.
What the price plan means
The current price is 477.36. An entry zone is the price range where a person might look to enter a trade, which is between 477.36 and 480.91. There are two target prices: 509.18 and 525.09. These are levels the price might reach. To manage risk, there is a stop-loss at 461.45. A stop-loss is an automatic instruction to exit a trade if the price drops to a certain level to prevent further loss. The reward-to-risk ratio is 2, which compares the potential gain to the potential loss.
What could make the idea fail
The scanner score is low at 20 out of 100. Also, the relative volume is 0.66, which means there is less trading activity than usual. If the price drops below the stop-loss level of 461.45, the setup fails.
Important reminder
This information is for educational purposes only and is not financial advice.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Caution (High confidence)
Vertex Pharmaceuticals (VRTX) shows mixed signals. Recent financial performance was strong, with an EPS of $4.47 and an 8.3% year-over-year revenue increase to $2.99 billion, surpassing analyst expectations. Institutional activity is divided; while the Healthcare of Ontario Pension Plan Trust Fund increased its stake by 23.4%, Sei Investments Co. reduced its position by 63.4%. Wall Street analysts maintain a 'Moderate Buy' consensus with an average price target of $559.61. However, the company has not distributed dividends over the past five years, and technical indicators show an oversold bullish reversal setup with a low technical score.
Potentially supportive context
- Surpassed analyst expectations with an EPS of $4.47 and 8.3% year-over-year revenue growth.
- Wall Street analysts maintain a 'Moderate Buy' consensus with an average target price of $559.61.
- The Healthcare of Ontario Pension Plan Trust Fund increased its stake by 23.4%.
Risks and caution items
- Sei Investments Co. reduced its position in the company by 63.4%.
- The company has not distributed dividends over the past five years.
- Technical score is low at 20 despite an oversold bullish reversal setup.
Latest reviewed article: Jul 26, 2026 11:38 am
Recent related articles
Merck & Co. Inc.'s stock performance is heavily influenced by its oncology division, particularly the Keytruda franchise, which has consistently delivered strong revenue growth. This growth helps offset other pharmaceutical segments' competitive pressures and patent expirations, providing a stable earnings outlook for…
The Healthcare of Ontario Pension Plan Trust Fund increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 23.4% in the first quarter, purchasing an additional 20,523 shares and bringing its total holdings to 108,251 shares valued at approximately $48.3 million. This strategic investment…
Sei Investments Co. significantly reduced its stake in Vertex Pharmaceuticals (VRTX) by 63.4% in the first quarter, selling 230,797 shares. Despite this, other institutional investors have slightly increased their positions in the pharmaceutical company. Analyst ratings for Vertex Pharmaceuticals generally remain positive,…
This article provides details on Vertex Pharmaceuticals Inc (VRTX) regarding its dividends and stock splits. It notes that the company has not distributed any dividends over the past five years. The page displays key financial data for VRTX, including its stock price,…
Zai Lab Ltd (ZLAB) reported its Q1 2026 earnings, beating EPS estimates by $0.07 with an actual EPS of -$0.46, though revenue of $99.91 million missed expectations by $8.52 million. The company highlighted strong clinical progress with Zoci and an expanding pipeline,…
Hemant Patel has been appointed as Vice President, Total Rewards, Organization Development & Culture at Vertex Pharmaceuticals. In this role, he will lead global initiatives in total rewards, organizational development, culture, talent, learning, and workforce strategy. Patel brings over 20 years of…
This article is a brief announcement from Investing.com reporting the filing of Form 4 for Vertex Pharmaceuticals Inc. The filing pertains to activity on July 24th. No specific details from the Form 4 are provided within the article.
Talphera Inc. (TLPH) is a specialty pharmaceutical company with relatively stable fundamentals and significant growth potential, though its valuation is considered fairly valued within the Pharmaceuticals industry. Institutional ownership is high, and analysts have given it "Buy" ratings with a target price…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- RSI is near oversold territory with bullish candle confirmation.